1. Lu MY, Zhang L, Li Y, et al. Recommendation of Diagnosis and Management for the Infections Related to Immune Checkpoint Inhibitors. Zhongguo Fei Ai Za Zhi, 2019, 22(10): 666-670. [陆旻雅, 张丽, 李玥, 等. 免疫检查点抑制剂相关感染诊治建 议. 中国肺癌杂志, 2019, 22(10): 666-670.] doi: 10.3779/j.issn.1009-3419.2019.10.11
2. Anastasopoulou, A., Ziogas, D.C., Samarkos, M. et al. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. j. immunotherapy cancer 7, 239 (2019). https:///10.1186/s40425-019-0717-7
3. Im Y, Lee J, Kim SJ, Koh W-J, Jhun BW, Lee S-H, Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors, Respiratory Medicine (2020), https:///10.1016/j.rmed. 2019.105853.
4. van Eeden R, Rapoport BL, Smit T and Anderson R (2019) Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review. Front. Oncol. 9:659.doi: 10.3389/fonc.2019.00659
5. 中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南,2019V1
6. Management of Immunotherapy-Related Toxicities, NCCN Version 1.2019.